Past performance is not indicative of future performance. Calculus has delivered an average ROI of 2.1x from Genedrive plc (AIM: GDR) through a number of exits in the VCT and EIS Funds. Genedrive, a company we had supported through scale-up, was founded as a contract research business (”CRO”) but refocussed as a Point of Care … Continued
Axol Bioscience, an established provider of iPSC-derived cells, media, and characterization services for life science discovery, today announced that it has raised £3.2 million
Calculus portfolio company Wonderhood Studios will be working with MADE to help creatively bring to life the brand’s vision, giving it a fresh and bold point of view
Important note: Past performance is not indicative of future performance. Tax benefits depend on the individual circumstances of each investor and may be subject to change in the future. Welcome to our first update of 2022. The run up to the tax year end is always a busy time and this year has been no … Continued
Calculus VCT has invested into Destiny Pharma, a clinical phase biotechnology company dedicated to the development of novel anti-infectives with a focus on infection prevention.
Invizius Awarded Major Biomedical Catalyst Grant to bring Anti-Inflammatory Haemodialysis Treatment to The Clinic
Arecor Granted Key U.S. Patent Protecting Proprietary Insulin Products, AT247 and AT278.
genedrive plc announces that the first six installations of the Antibiotic Induced Hearing Loss system have been deployed to Manchester University NHS Foundation Trust
Calculus Capital is looking to appoint a Chief Operating Officer. The individual will support the CEO in implementing organisational vision and operational strategy.
Calculus Capital is looking for someone to fill the role of Fund Admin Analyst.
Netflix has ordered Brouhaha Entertainment’s adaptation of Trent Dalton’s Boy Swallows Universe, more than two years after publisher HarperCollins announced it had sold the screen rights to the author’s debut novel.
MIP Diagnostics, a UK nanotechnology business has secured increased investment of its previous round of funding, totalling £7.3M. The joint investment comes from Mercia Asset Management, Calculus Capital, Downing Ventures and BGF, along with an original angel investor.
Above the Line Productions (a subsidiary of Raindog Films), 101 Studios, Campfire Studios and PZAJ have announced their partnership for a documentary feature on the backdoor dealings and mafia-style tactics plaguing the international governing body, FIFA.
eConsult have won a contract to implement their eTriage system in Homerton Emergency Department to enable an electronic check-in service.
Calculus EIS, VCT and Creative Content EIS portfolio company today released the Devil’s Advocate: The Mostly True Story of Giovanni Di Stefano, on Sky and NowTV.
Maze Theory shares held by Calculus Capital EIS Funds and the Calculus VCT plc have been purchased by a strategic investor, Pluto Digital
The essence of eConsult is to ask the questions ahead of the consultation. We gather information 24 hours a day, at the patient’s convenience
Important note: Performance is not indicative of future performance. Tax benefits depend on the individual circumstances of each investor and may be subject to change in the future. Co-head of investments Richard Moore recently spoke to Wealth Club about Calculus and our VCT offering.
Important note: Past performance is not indicative of future performance. Tax benefits depend on the individual circumstances of each investor and may be subject to change in the future. By Oliver Warren, Investor Relations Associate In the 21/22 tax year, £1.13bn was invested in VCTs*, a record amount and a more than impressive show of … Continued
The story behind Wonderhood’s new documentary featured in The Telegraph. He is known as the ‘Devil’s Advocate’, and rarely can there have been a more deliciously appropriate epithet. In a legal career that seemingly knew no bounds, Giovanni di Stefano claimed to have offered counsel to Osama bin Laden, Saddam Hussein, Slobodan Milošević, Arkan, Robert … Continued
Arecor’s AT247 has the opportunity to revolutionise diabetic management through creating in effect an artificial pancreas through a closed loop system Over 500 million people suffer with diabetes worldwide and AT247 has the potential to make both management easier and improve average blood glucose levels Arecor Therapeutics plc, the biopharmaceutical group advancing today’s therapies to … Continued
Important note: Past performance is not indicative of future performance. Tax benefits depend on the individual circumstances of each investor and may be subject to change in the future. Welcome to our final quarterly update of 2021. This has been a record-breaking year for Calculus as we have delivered 11 exits and over £50million back to … Continued
By Matthew Moynes, Assistant Director of Investor Relations, Calculus Capital Important note: Past performance is not indicative of future performance. Tax benefits depend on the individual circumstances of each investor and may be subject to change in the future. Synonymous with UK venture capital investing is the attractive tax incentives provided by HMRC which help … Continued
UK-based technology company Hinterview has today announced that it has raised £3m in Series A funding. The award-winning video platform for the recruitment sector has experienced soaring demand for their technology, with growth continuing this year as the recruitment industry bounces back in a new era of hybrid-first working. This Series A round, led by … Continued